middle.news
How Clarity’s New Deal Could Revolutionize Prostate Cancer Diagnostics in the US
9:46am on Tuesday 17th of June, 2025 AEST
•
Healthcare
Read Story
How Clarity’s New Deal Could Revolutionize Prostate Cancer Diagnostics in the US
9:46am on Tuesday 17th of June, 2025 AEST
Key Points
Five-year commercial manufacturing agreement with SpectronRx
Capacity to produce up to 400,000 patient-ready doses annually
On-demand production and distribution across all 50 US states
Option to expand manufacturing to additional regional hubs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CU6
OPEN ARTICLE